Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis
Gastric Cancer · 2024
DOI: 10.1007/s10120-024-01516-3 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Gastric Cancer, 2024. Verfasst von Yoon-Koo Kang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology Asan Medical Centre, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, South Korea. ykk…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Esophagogastric Junction, Fluorouracil. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen.
Abstract (Originalsprache)
Background
In the FIGHT study (NCT03694522) bemarituzumab, a humanized monoclonal antibody selective for fibroblast growth factor receptor 2b (FGFR2b), plus mFOLFOX6 showed clinically meaningful efficacy in patients with FGFR2b-positive (2+/3+ membranous staining by immunohistochemistry) locally advanced unresectable/metastatic gastric/gastroesophageal cancer (G/GEJC). A meaningful proportion of patients in FIGHT were enrolled in East Asia, reflecting global epidemiology of G/GEJC.
Methods
This subgroup analysis of the global, phase 2, double-blind FIGHT study included all patients enrolled in East Asian sites. Patients were randomized 1:1 to bemarituzumab-mFOLFOX6 (15 mg/kg and one 7.5 mg/kg dose on cycle 1, day 8) or matching placebo-mFOLFOX6. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate, and safety. Efficacy was evaluated after a minimum follow-up of 24 months.
Results
The East Asian subgroup comprised 89 patients (57% of overall study population); 45 were randomized to bemarituzumab-mFOLFOX6 and 44 to placebo-mFOLFOX6. Median PFS (95% confidence interval [CI]) was 12.9 months (8.8–17.9) with bemarituzumab-mFOLFOX6 and 8.2 months (5.6–10.3) with placebo-mFOLFOX6 (HR 0.50, 95% CI 0.29–0.87); median OS (95% CI) was 24.7 months (13.8–33.1) vs 12.9 months (9.3–21.4), respectively (HR 0.56, 95% CI 0.32–0.96). Treatment benefit was more pronounced in patients with FGFR2b-positive G/GEJC in ≥ 10% of tumor cells. No new safety signals were reported.
Conclusion
In East Asian patients with FGFR2b-positive advanced/metastatic G/GEJC enrolled in the global FIGHT study, bemarituzumab-mFOLFOX6 showed clinically meaningful outcomes over placebo-mFOLFOX6.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology Asan Medical Centre, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, South Korea. ykkang@amc.seoul.kr.
- Nanjing Tianyinshan Hospital, The First Affiliated Hospital of China Pharmaceutical University, Nanjing, China.
- Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-Do, South Korea.
- Department of Internal Medicine, Korea University Guro Hospital, Seoul, South Korea.
- Department of Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
- Kyungpook National University Chilgok Hospital, Daegu, South Korea.
ORCID-Profile: Yoon-Koo Kang
Förderung
- Amgen
Zitieren
APA
Kang, Y. K., Qin, S., Lee, K. W., Oh, S. C., Kim, I. H., Kim, J. G., Li, Y., Yan, Z., Li, J., Bai, L. Y., Chan, C., Yusuf, A., Zahlten-Kümeli, A., Taylor, K., & Yamaguchi, K. (2024). Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis. Gastric Cancer. https://doi.org/10.1007/s10120-024-01516-3
Vancouver
Kang YK, Qin S, Lee KW, Oh SC, Kim IH, Kim JG, et al. Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis. Gastric Cancer. 2024. doi:10.1007/s10120-024-01516-3
BibTeX
@article{Kang2024,
author = {Kang, Yoon-Koo and Qin, Shukui and Lee, Keun-Wook and Oh, Sang Cheul and Kim, In-Ho and Kim, Jong Gwang and Li, Yong and Yan, Zhuchen and Li, Jin and Bai, Li-Yuan and Chan, Catherine and Yusuf, Akeem and Zahlten-Kümeli, Anita and Taylor, Kate and Yamaguchi, Kensei},
title = {Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis},
journal = {Gastric Cancer},
year = {2024},
doi = {10.1007/s10120-024-01516-3}
}
EUVIMED